EDAP TMS (FOCL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 May, 2026Executive summary
Ordinary and Extraordinary General Meeting scheduled for June 26, 2026, in Vaulx-en-Velin, France.
Shareholders are invited to vote on a comprehensive agenda covering director renewals, financial approvals, compensation, capital structure, and bylaw amendments.
Voting matters and shareholder proposals
Proposals include renewal of director terms, ratification of a temporary director, and approval of related-person agreements.
Approval of statutory and consolidated financial statements for the year ended December 31, 2025.
Advisory votes on executive compensation and frequency of future say-on-pay votes.
Multiple delegations of authority to the Board for capital increases, with or without preferential subscription rights, including for specific categories of investors and the European Investment Bank.
Amendments to bylaws regarding share capital, Board of Directors, and Shareholders' Meeting.
Board of directors and corporate governance
Renewal of terms for five directors and ratification of a temporary director appointed in February 2026.
Amendments proposed to bylaws affecting the Board of Directors.
Latest events from EDAP TMS
- Q2 2026 revenue up 39% to $13.2M, gross margin 55.6%, net loss $14.4M, $40M raised.FOCL
Q2 2026 - Robotic focal therapy growth accelerates with HIFU innovation, new indications, and global expansion.FOCL
Jefferies Global Healthcare Conference 2026 - Robotic focal therapy platform accelerates HIFU growth, innovation, and expansion into new indications.FOCL
Investor Day 2026 - 2025 featured significant HIFU milestones, a €25.9M net loss, and new EIB financing.FOCL
Proxy filing - Record HIFU growth, expanded indications, and broad capital authorizations headline 2026 proxy.FOCL
Proxy filing - Record Q1 revenue and 78% HIFU growth offset by higher net loss and cash outflow.FOCL
Q1 2026 - Record HIFU growth, new EIB financing, and 32 key resolutions headline the 2026 proxy.FOCL
Proxy filing - Up to $125 million in shares and warrants registered for flexible future offerings.FOCL
Registration filing - Record HIFU growth and clinical milestones drive strong expansion and improved financials.FOCL
Q4 2024